Compugen signals leadership transition and advances COM701 ovarian cancer trial with interim data targeted for 2026
Source: SeekingAlpha
2025-08-07 06:30:57 ET
More on Compugen
- Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
- Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Compugen
- Historical earnings data for Compugen
- Financial information for Compugen
Read the full article on Seeking Alpha
For further details see:
Compugen signals leadership transition and advances COM701 ovarian cancer trial with interim data targeted for 2026
Compugen Ltd.
NASDAQ: CGEN
CGEN Trading
-3.7% G/L:
$2.215 Last:
124,106 Volume:
$2.21 Open:
CGEN Latest News
CGEN Stock Data
$165,050,413
90,614,080
N/A
90
N/A
Biotechnology & Life Sciences
Healthcare
IL
Holon
